TACLONEX TOPICAL SUSPENSION Rx
Generic Name and Formulations:
Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%.
LEO Pharma Inc.
Indications for TACLONEX TOPICAL SUSPENSION:
Plaque psoriasis of the scalp in patients 12–17yrs. Plaque psoriasis of the scalp and body in patients ≥18yrs.
Apply to affected areas once daily for up to 8 weeks or until clear. 12–17yrs: max 60g/week. ≥18yrs: max 100g/week. Do not occlude.
Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, or irritation occurs. Do not use on face, axillae, or groin, or if atrophy is present at treatment site. Avoid eyes, sun, UV light (eg, phototherapy). Treat infection if present. Allergic contact dermatitis. Pregnancy (Cat.C). Nursing mothers.
Vit. D3 derivative + topical steroid.
Systemic absorption potentiated by other corticosteroids.
Oint: pruritus, scaly rash. Susp: folliculitis, burning sensation of skin.
Oint—60g, 100g; Susp—60g, 2x60g
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC